LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Kodu・Aktsiate loetelu・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Suletud

1.27 2.42

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.23

Max

1.31

Põhinäitajad
By Trading Economics
Sissetulek	17M -26M
Töötajad	171
EBITDA	19M -23M

Soovitused
By TipRanks
Soovitused	Müü
12 kuu keskmine prognoos	+57.48% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	-24M 78M
Eelmine avamishind	-1.15
Eelmine sulgemishind	1.27

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.43 / 1.6 Toetus ja vastupanu

Pliant Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

3. märts 2026, 18:43 UTC

Uudisväärsed sündmused

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

3. märts 2026, 17:33 UTC

Omandamised, ülevõtmised, äriostud

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

3. märts 2026, 23:45 UTC

Market Talk

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

3. märts 2026, 23:44 UTC

Market Talk

Uudisväärsed sündmused

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

3. märts 2026, 23:25 UTC

Market Talk

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

3. märts 2026, 23:25 UTC

Market Talk

Global Energy Roundup: Market Talk

3. märts 2026, 22:38 UTC

Uudisväärsed sündmused

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

3. märts 2026, 22:16 UTC

Tulu

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

3. märts 2026, 22:09 UTC

Tulu

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

3. märts 2026, 22:06 UTC

Tulu

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

3. märts 2026, 22:05 UTC

Tulu

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

3. märts 2026, 22:03 UTC

Tulu

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

3. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Tech, Media & Telecom Roundup: Market Talk

3. märts 2026, 21:50 UTC

Market Talk

Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

3. märts 2026, 21:45 UTC

Uudisväärsed sündmused

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

3. märts 2026, 21:37 UTC

Tulu

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

3. märts 2026, 21:26 UTC

Uudisväärsed sündmused

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

3. märts 2026, 20:31 UTC

Market Talk

Uudisväärsed sündmused

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

3. märts 2026, 20:04 UTC

Market Talk

Uudisväärsed sündmused

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

3. märts 2026, 19:17 UTC

Market Talk

Uudisväärsed sündmused

Gold and Silver Drop as Energy Surges -- Market Talk

3. märts 2026, 18:43 UTC

Tulu

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

3. märts 2026, 18:29 UTC

Market Talk

Uudisväärsed sündmused

Global Energy Roundup: Market Talk

3. märts 2026, 18:29 UTC

Market Talk

Uudisväärsed sündmused

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

3. märts 2026, 18:22 UTC

Uudisväärsed sündmused

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

3. märts 2026, 18:22 UTC

Uudisväärsed sündmused

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

3. märts 2026, 18:17 UTC

Market Talk

Uudisväärsed sündmused

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

3. märts 2026, 18:14 UTC

Tulu

How Long Can Anthropic Play Defense? -- WSJ

3. märts 2026, 17:41 UTC

Uudisväärsed sündmused

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

3. märts 2026, 17:36 UTC

Uudisväärsed sündmused

Iran Conflict is Starting to Boost Gasoline Prices -- Update

3. märts 2026, 17:28 UTC

Omandamised, ülevõtmised, äriostud

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Võrdlus sarnastega

Hinnamuutus

Pliant Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

57.48% tõus

12 kuu keskmine prognoos

Keskmine 2 USD 57.48%

Kõrge 2 USD

Madal 2 USD

Põhineb 2 Wall Streeti analüütiku instrumendi Pliant Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Müü

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi Pliant Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.43 / 1.6Toetus ja vastupanu

Recent bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.